$MDGL
MADRIGAL PHARMACEUTICALS, INC.

2013 Q1 Form 10-K Financial Statement

#000104746913002698 Filed on March 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2011 Q4 2011 Q3
Revenue $0.00 $121.0K $521.0K
YoY Change -100.0% -96.98% -84.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.900M $2.800M $3.100M
YoY Change 50.0% -9.68% 19.23%
% of Gross Profit
Research & Development $16.38M $10.86M $10.75M
YoY Change 35.75% 16.76% -2.47%
% of Gross Profit
Depreciation & Amortization $100.0K $290.0K $400.0K
YoY Change -56.52% -36.96% -14.89%
% of Gross Profit
Operating Expenses $20.26M $13.66M $13.88M
YoY Change 37.7% 10.18% 1.97%
Operating Profit -$20.26M -$10.24M -$12.22M
YoY Change 39.09% 19.42%
Interest Expense -$470.0K -$504.0K -$516.0K
YoY Change -3.29% 0.8% 1564.52%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$20.70M -$10.70M -$12.70M
YoY Change 37.09% 21.59% 23.3%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.70M -$10.70M -$12.70M
YoY Change 37.09% 21.59% 23.3%
Net Earnings / Revenue -8842.98% -2437.62%
Basic Earnings Per Share
Diluted Earnings Per Share -$10.35M -$7.643M -$9.071M
COMMON SHARES
Basic Shares Outstanding 69.05M shares 49.50M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2011 Q4 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.40M $39.70M $50.70M
YoY Change 57.49% -22.16% -6.28%
Cash & Equivalents $34.96M $30.08M $20.60M
Short-Term Investments $55.40M $9.700M $30.00M
Other Short-Term Assets $1.500M $600.0K $1.400M
YoY Change 150.0% 50.0% 100.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $91.87M $40.29M $52.02M
YoY Change 58.4% -21.81% -5.07%
LONG-TERM ASSETS
Property, Plant & Equipment $1.350M $1.407M $1.300M
YoY Change 1.96% -35.49% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $481.0K $631.0K $500.0K
YoY Change -7.32% 72.4% 0.0%
Total Long-Term Assets $1.831M $2.038M $1.846M
YoY Change -0.65% -19.98% -40.45%
TOTAL ASSETS
Total Short-Term Assets $91.87M $40.29M $52.02M
Total Long-Term Assets $1.831M $2.038M $1.846M
Total Assets $93.70M $42.32M $53.87M
YoY Change 56.58% -21.72% -6.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.719M $3.467M $2.900M
YoY Change 88.13% 80.1% 20.83%
Accrued Expenses $7.700M $7.400M $6.300M
YoY Change 18.46% 10.45% 5.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $3.100M $4.200M $4.600M
YoY Change -49.18% 20.0% 1433.33%
Total Short-Term Liabilities $16.55M $15.15M $17.12M
YoY Change 5.8% -9.49% 14.87%
LONG-TERM LIABILITIES
Long-Term Debt $20.50M $12.40M $12.20M
YoY Change 97.12% 5.98% -8.96%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $20.55M $12.40M $12.17M
YoY Change 97.04% -10.47% -27.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.55M $15.15M $17.12M
Total Long-Term Liabilities $20.55M $12.40M $12.17M
Total Liabilities $37.10M $27.55M $29.29M
YoY Change 42.29% -9.93% -7.32%
SHAREHOLDERS EQUITY
Retained Earnings -$398.4M
YoY Change 13.5%
Common Stock $538.5M $413.2M
YoY Change 20.42% 10.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.60M $14.77M $24.60M
YoY Change
Total Liabilities & Shareholders Equity $93.70M $42.32M $53.87M
YoY Change 56.58% -21.72% -6.96%

Cashflow Statement

Concept 2013 Q1 2011 Q4 2011 Q3
OPERATING ACTIVITIES
Net Income -$20.70M -$10.70M -$12.70M
YoY Change 37.09% 21.59% 23.3%
Depreciation, Depletion And Amortization $100.0K $290.0K $400.0K
YoY Change -56.52% -36.96% -14.89%
Cash From Operating Activities -$22.21M -$10.49M -$11.82M
YoY Change 45.64% 27.77% 40.21%
INVESTING ACTIVITIES
Capital Expenditures $276.0K -$380.0K -$260.0K
YoY Change 87.76% 1166.67% 271.43%
Acquisitions
YoY Change
Other Investing Activities -$36.34M $20.37M $6.970M
YoY Change 175.93% -4528.26% -152.96%
Cash From Investing Activities -$36.62M $19.99M $6.710M
YoY Change 174.92% -4264.58% -150.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.045M
YoY Change -96.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.28M -70.00K -130.0K
YoY Change -62.84% -101.37% -100.93%
NET CHANGE
Cash From Operating Activities -22.21M -10.49M -11.82M
Cash From Investing Activities -36.62M 19.99M 6.710M
Cash From Financing Activities 12.28M -70.00K -130.0K
Net Change In Cash -46.55M 9.430M -5.240M
YoY Change -1139.06% -362.67% -31.95%
FREE CASH FLOW
Cash From Operating Activities -$22.21M -$10.49M -$11.82M
Capital Expenditures $276.0K -$380.0K -$260.0K
Free Cash Flow -$22.49M -$10.11M -$11.56M
YoY Change 46.04% 23.59% 38.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q2 dei Entity Public Float
EntityPublicFloat
206423923 USD
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69054951 shares
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49539808 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68930082 shares
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49539808 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68930082 shares
CY2010 snta Stock Issued During Period Value Related Party
StockIssuedDuringPeriodValueRelatedParty
8460000 USD
CY2010 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
316000 USD
CY2010 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4048000 USD
CY2011 snta Stock Issued During Period Value Related Party
StockIssuedDuringPeriodValueRelatedParty
7734000 USD
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
479000 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3354000 USD
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
24911000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
23479000 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
3354000 USD
CY2010 us-gaap Share Based Compensation
ShareBasedCompensation
4048000 USD
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1464000 USD
CY2010 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1933000 USD
CY2011 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
50726000 USD
CY2010 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
36916000 USD
CY2011 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
60745000 USD
CY2010 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
17250000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
690000 USD
CY2010 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
136000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
9329000 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-19802000 USD
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27581000 USD
CY2010 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23530000 USD
CY2011 snta Proceeds From Issuance Of Common Stock To Related Parties
ProceedsFromIssuanceOfCommonStockToRelatedParties
7734000 USD
CY2010 snta Proceeds From Issuance Of Common Stock To Related Parties
ProceedsFromIssuanceOfCommonStockToRelatedParties
8460000 USD
CY2011 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2000000 USD
CY2010 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
15000000 USD
CY2011 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
378000 USD
CY2010 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1834000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
36736000 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
45156000 USD
CY2011 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-1235000 USD
CY2010 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-12845000 USD
CY2011 us-gaap Interest Paid
InterestPaid
1911000 USD
CY2010 us-gaap Interest Paid
InterestPaid
578000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9943000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
115515000 USD
CY2012 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
51437000 USD
CY2012 us-gaap Nature Of Operations
NatureOfOperations
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b>(1) Nature of Business</b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Synta Pharmaceuticals Corp. (the Company) was incorporated in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has incurred significant operating losses since its inception and, as a result, at December&#160;31, 2012 had an accumulated deficit of $461.2&#160;million. Operations have been funded principally through the sale of common stock and convertible preferred stock, capital leases, non-refundable payments under the former collaboration agreements with GlaxoSmithKline (GSK) and Hoffman-La Roche (Roche), and proceeds from term loans by General Electric Capital Corporation (GECC) and Oxford Finance Corporation (Oxford) (see Note&#160;10). At December&#160;31, 2012, the Company had approximately $100.6&#160;million in cash, cash equivalents and marketable securities.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on the Company's current operating levels, it expects its cash resources will be sufficient to fund operations into the second quarter of 2014. This estimate assumes that certain activities contemplated for 2013 will be conducted subject to the availability of sufficient financial resources. The Company expects to continue evaluating additional potential sources of funding, including partnership agreements, cost or risk-sharing agreements, equity financings or other sources.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company may require significant additional funds earlier than it currently expects in order to conduct additional clinical trials and continue to fund its operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all.</font></p></div>
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2162000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2160000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2196000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1965000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
8483000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
13000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
1000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
14000 USD
CY2012Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
0 USD
CY2012Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
14000 USD
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1900000 USD
CY2010 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2000000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3272000 USD
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2914000 USD
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
999000 USD
CY2011Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1069000 USD
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2200000 USD
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b>Use of Estimates</b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under its collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</font></p></div>
CY2012 snta Patent Expenses
PatentExpenses
1800000 USD
CY2011 snta Patent Expenses
PatentExpenses
2300000 USD
CY2010 snta Patent Expenses
PatentExpenses
1900000 USD
CY2011Q1 snta Amount Of Grant Awarded
AmountOfGrantAwarded
1000000 USD
CY2010Q4 snta Amount Of Grant Awarded
AmountOfGrantAwarded
1000000 USD
CY2012 snta Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.10 pure
CY2012 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 item
CY2011Q4 snta Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains
CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains
3000 USD
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20765000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21270000 USD
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19358000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20096000 USD
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
738000 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3354000 USD
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4048000 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3322000 USD
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16109000 USD
CY2011 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2379000 USD
CY2011 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
84000 USD
CY2011 snta Income Tax Reconciliation State And Local Operating Loss Expiration Amount
IncomeTaxReconciliationStateAndLocalOperatingLossExpirationAmount
2867000 USD
CY2011 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
373000 USD
CY2011 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1537000 USD
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
259000 USD
CY2011 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
16442000 USD
CY2010 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-12739000 USD
CY2010 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1967000 USD
CY2010 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
196000 USD
CY2010 snta Income Tax Reconciliation State And Local Operating Loss Expiration Amount
IncomeTaxReconciliationStateAndLocalOperatingLossExpirationAmount
3820000 USD
CY2010 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
791000 USD
CY2010 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1686000 USD
CY2010 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-78000 USD
CY2010 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
11663000 USD
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-21349000 USD
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3220000 USD
CY2012 snta Income Tax Reconciliation State And Local Operating Loss Expiration Amount
IncomeTaxReconciliationStateAndLocalOperatingLossExpirationAmount
3167000 USD
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
382000 USD
CY2012 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
411000 USD
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
22000 USD
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
21409000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
16796000 USD
CY2011Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
2776000 USD
CY2011Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
667000 USD
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
148779000 USD
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
148779000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
17225000 USD
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
2594000 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1014000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
170189000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
170189000 USD
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16400000 USD
CY2010 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11700000 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
21400000 USD
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
372000 USD
CY2010 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
429000 USD
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
376000 USD
CY2011Q2 snta License And Milestone Revenues
LicenseAndMilestoneRevenues
1143000 USD
CY2011Q1 snta License And Milestone Revenues
LicenseAndMilestoneRevenues
1143000 USD
CY2011Q3 snta License And Milestone Revenues
LicenseAndMilestoneRevenues
1143000 USD
CY2011Q4 snta License And Milestone Revenues
LicenseAndMilestoneRevenues
3302000 USD
CY2011Q1 snta Collaborative Revenues
CollaborativeRevenues
1143000 USD
CY2011Q2 snta Collaborative Revenues
CollaborativeRevenues
1143000 USD
CY2011Q3 snta Collaborative Revenues
CollaborativeRevenues
1143000 USD
CY2011Q4 snta Collaborative Revenues
CollaborativeRevenues
3302000 USD
CY2011Q2 us-gaap Revenue From Grants
RevenueFromGrants
211000 USD
CY2011Q3 us-gaap Revenue From Grants
RevenueFromGrants
521000 USD
CY2011Q4 us-gaap Revenue From Grants
RevenueFromGrants
121000 USD
CY2011Q1 snta Total Revenues
TotalRevenues
1143000 USD
CY2011Q2 snta Total Revenues
TotalRevenues
1354000 USD
CY2011Q3 snta Total Revenues
TotalRevenues
1664000 USD
CY2011Q4 snta Total Revenues
TotalRevenues
3423000 USD
CY2011Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9436000 USD
CY2011Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10417000 USD
CY2011Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10751000 USD
CY2011Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10859000 USD
CY2011Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2803000 USD
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3131000 USD
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2946000 USD
CY2011Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2673000 USD
CY2011Q1 us-gaap Operating Expenses
OperatingExpenses
12109000 USD
CY2011Q2 us-gaap Operating Expenses
OperatingExpenses
13363000 USD
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
13882000 USD
CY2011Q4 us-gaap Operating Expenses
OperatingExpenses
13662000 USD
CY2011Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10966000 USD
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12009000 USD
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12218000 USD
CY2011Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10239000 USD
CY2011Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11401000 USD
CY2011Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12502000 USD
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12734000 USD
CY2011Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10743000 USD
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2011Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2011Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42008818 shares
CY2011Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47845315 shares
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49403589 shares
CY2011Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49426806 shares
CY2012 snta Common Stock Voting Rights Number
CommonStockVotingRightsNumber
1 item
CY2012Q4 snta Cash And Cash Equivalents And Available For Sale Securities Gross Unrealized Gains
CashAndCashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGains
3000 USD
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7919000 USD
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M10D
CY2012Q1 us-gaap Revenue From Grants
RevenueFromGrants
147000 USD
CY2012Q1 snta Total Revenues
TotalRevenues
147000 USD
CY2012Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12066000 USD
CY2012Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11252000 USD
CY2012Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11743000 USD
CY2012Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14351000 USD
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2646000 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2882000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2796000 USD
CY2012Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3352000 USD
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
14712000 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
14134000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
14539000 USD
CY2012Q4 us-gaap Operating Expenses
OperatingExpenses
17703000 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14565000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14134000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14539000 USD
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-17703000 USD
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15051000 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14620000 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14996000 USD
CY2012Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18123000 USD
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56366992 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57650412 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60661720 shares
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62914546 shares
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1141000 USD
CY2012 snta Stock Issued During Period Value Related Party
StockIssuedDuringPeriodValueRelatedParty
53545000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3322000 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44155000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31310000 USD
CY2010 snta Stock Issued During Period Value New Issues Excluding Sales To Related Parties
StockIssuedDuringPeriodValueNewIssuesExcludingSalesToRelatedParties
23214000 USD
CY2011 snta Stock Issued During Period Value New Issues Excluding Sales To Related Parties
StockIssuedDuringPeriodValueNewIssuesExcludingSalesToRelatedParties
27102000 USD
CY2012 snta Stock Issued During Period Value New Issues Excluding Sales To Related Parties
StockIssuedDuringPeriodValueNewIssuesExcludingSalesToRelatedParties
65107000 USD
CY2012Q4 us-gaap Share Price
SharePrice
9.02
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
856000 USD
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
611000 USD
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
123463000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
143988000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
5077000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
5368000 USD
CY2012Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
100600000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81512000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30075000 USD
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
19087000 USD
CY2011Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
9650000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
786000 USD
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
561000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
101385000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
40286000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1174000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1407000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
458000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
631000 USD
CY2012Q4 us-gaap Assets
Assets
103017000 USD
CY2011Q4 us-gaap Assets
Assets
42324000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5661000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3467000 USD
CY2012Q4 snta Accrued Contract Research Costs
AccruedContractResearchCosts
4761000 USD
CY2011Q4 snta Accrued Contract Research Costs
AccruedContractResearchCosts
2841000 USD
CY2012Q4 snta Accrued Liabilities Current Excluding Accrued Contract Research Costs
AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts
5127000 USD
CY2011Q4 snta Accrued Liabilities Current Excluding Accrued Contract Research Costs
AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts
4594000 USD
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
13000 USD
CY2011Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
12000 USD
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
7924000 USD
CY2011Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
4234000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23486000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15148000 USD
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
1000 USD
CY2011Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
14000 USD
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
4464000 USD
CY2011Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
12388000 USD
CY2012Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4465000 USD
CY2011Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
12402000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
27951000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
27550000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
7000 USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
536277000 USD
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
413196000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-461220000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-398430000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
75066000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
14774000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103017000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42324000 USD
CY2011 snta License And Milestone Revenues
LicenseAndMilestoneRevenues
6731000 USD
CY2010 snta License And Milestone Revenues
LicenseAndMilestoneRevenues
4572000 USD
CY2010 snta Cost Sharing Reimbursements
CostSharingReimbursements
9253000 USD
CY2011 snta Collaborative Revenues
CollaborativeRevenues
6731000 USD
CY2010 snta Collaborative Revenues
CollaborativeRevenues
13825000 USD
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
147000 USD
CY2011 us-gaap Revenue From Grants
RevenueFromGrants
853000 USD
CY2010 us-gaap Revenue From Grants
RevenueFromGrants
978000 USD
CY2012 snta Total Revenues
TotalRevenues
147000 USD
CY2011 snta Total Revenues
TotalRevenues
7584000 USD
CY2010 snta Total Revenues
TotalRevenues
14803000 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11676000 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11552000 USD
CY2010 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11449000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-60941000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-45432000 USD
CY2010 us-gaap Operating Income Loss
OperatingIncomeLoss
-36898000 USD
CY2012 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1849000 USD
CY2011 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1948000 USD
CY2010 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-569000 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62790000 USD
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47380000 USD
CY2010 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37467000 USD
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
CY2010 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59411476 shares
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47197572 shares
CY2010 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40365215 shares
CY2012 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1000 USD
CY2011 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000 USD
CY2010 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62791000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
3322000 USD
CY2011 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-116000 USD
CY2010 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
116000 USD
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
225000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
130000 USD
CY2010 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12000 USD
CY2012 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-173000 USD
CY2011 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
265000 USD
CY2010 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
8000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2194000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1542000 USD
CY2010 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2032000 USD
CY2012 snta Increase Decrease Accrued Contract And Research Costs
IncreaseDecreaseAccruedContractAndResearchCosts
1920000 USD
CY2011 snta Increase Decrease Accrued Contract And Research Costs
IncreaseDecreaseAccruedContractAndResearchCosts
330000 USD
CY2010 snta Increase Decrease Accrued Contract And Research Costs
IncreaseDecreaseAccruedContractAndResearchCosts
412000 USD
CY2012 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
533000 USD
CY2011 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
400000 USD
CY2010 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-310000 USD
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6731000 USD
CY2010 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4647000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-54135000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-47300000 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38199000 USD
CY2012 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
50033000 USD
CY2012 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
40595000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
505000 USD
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
66248000 USD
CY2012 snta Proceeds From Issuance Of Common Stock To Related Parties
ProceedsFromIssuanceOfCommonStockToRelatedParties
53545000 USD
CY2012 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
4234000 USD
CY2012 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
12000 USD
CY2012 us-gaap Interest Paid
InterestPaid
1696000 USD
CY2012 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
32000 USD
CY2012 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
32000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47374000 USD
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37470000 USD
CY2012 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06 pure
CY2012 snta Defined Contribution Plan Employers Matching Contribution Vesting Period
DefinedContributionPlanEmployersMatchingContributionVestingPeriod
P3Y
CY2012 snta Deductions Related To Exercise Of Common Stock Options Included In Net Operating Loss Carryforwards
DeductionsRelatedToExerciseOfCommonStockOptionsIncludedInNetOperatingLossCarryforwards
1100000 USD
CY2011Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-435000 USD
CY2011Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-493000 USD
CY2011Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-516000 USD
CY2011Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-504000 USD
CY2012Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-486000 USD
CY2012Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-486000 USD
CY2012Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-457000 USD
CY2012Q4 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-420000 USD
CY2012 snta Number Of Non Cancelable And Renewable Operating Leases
NumberOfNonCancelableAndRenewableOperatingLeases
3 item

Files In Submission

Name View Source Status
0001047469-13-002698-index-headers.html Edgar Link pending
0001047469-13-002698-index.html Edgar Link pending
0001047469-13-002698.txt Edgar Link pending
0001047469-13-002698-xbrl.zip Edgar Link pending
a2213560z10-k.htm Edgar Link pending
a2213560zex-10_66.htm Edgar Link pending
a2213560zex-23_1.htm Edgar Link pending
a2213560zex-31_1.htm Edgar Link pending
a2213560zex-31_2.htm Edgar Link pending
a2213560zex-32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g216131.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snta-20121231.xml Edgar Link completed
snta-20121231.xsd Edgar Link pending
snta-20121231_cal.xml Edgar Link unprocessable
snta-20121231_def.xml Edgar Link unprocessable
snta-20121231_lab.xml Edgar Link unprocessable
snta-20121231_pre.xml Edgar Link unprocessable